SCHEMBL22256990

SCHEMBL22256990

CCN1CCC2(CCCC(=O)N2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1LG2 Q9BQ51 7/20 0.42
CD274 Q9NZQ7 7/20 0.42
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
POLB P06746 1/20 0.33
CYP2D6 P10635 1/20 0.33
ALOX5 P09917 2/20 0.32
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31
OPRK1 P41145 1/20 0.31
PRMT1 Q99873 1/20 0.31
CRBN Q96SW2 1/20 0.31
LTA4H P09960 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21739459 0.89 CYP11B1 (0.47) PDCD1LG2CD274CYP11B1CYP11B2KDM4E
SCHEMBL21673277 0.82 PDCD1LG2 (0.38) PDCD1LG2CD274CYP11B1CYP11B2KDM4E
SCHEMBL16751004 0.80 NEK2 (0.46) PDCD1LG2CD274CYP11B1CYP11B2KMT2A
SCHEMBL25270633 0.77
SCHEMBL20312857 0.76 CYP11B1 (0.36) PDCD1LG2CD274CYP11B1CYP11B2KMT2A
SCHEMBL16750019 0.76 CYP11B1 (0.36) PDCD1LG2CD274CYP11B1CYP11B2KMT2A
SCHEMBL9302395 0.75 CRBN (0.43) PDCD1LG2CD274CYP11B1CYP11B2KMT2A
SCHEMBL31599526 0.75 CRBN (0.43) PDCD1LG2CD274CYP11B1CYP11B2KMT2A
SCHEMBL22053044 0.73 KDM4E (0.36) PDCD1LG2CD274KDM4EOPRM1OPRD1
SCHEMBL21673296 0.73 CYP11B1 (0.44) PDCD1LG2CD274CYP11B1CYP11B2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200230117-A1 NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE IOMET PHARMA LTD. (GB) 2020-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200230117-A1 NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE IDO1, IDO2, TDO2 PDCD1LG2 2563/4885CD274 2968/4885CYP11B1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.